OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Treatment Reviews is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	289
Editorial Board	191
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis	155
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	126
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	107
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	103
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors	103
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	99
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	91
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology	89
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	87
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming	85
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	78
Editorial Board	76
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era	73
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	68
Optimizing care in early phase cancer trials: The role of palliative care	66
Progress toward personalized management of stage II/III triple negative breast cancer	63
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	62
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	61
Proton therapy in breast cancer: bridging medical and radiation oncology	60
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	59
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	59
De-escalation strategies with targeted therapies in non-small cell lung cancer	59
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	58

FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	57
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	55
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation	55
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	55
Uncertainties and controversies in axillary management of patients with breast cancer	54
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	54
Editorial Board	52
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	52
Editorial Board	52
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation	51
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	51
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	51
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	50
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	49
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	48
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	47
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?	46
Editorial Board	45
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]	43
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)	43